These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 20576822)

  • 41. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
    Lima F; Mawad H; El-Husseini AA; Davenport DL; Malluche HH
    Clin Nephrol; 2019 Apr; 91(4):222-230. PubMed ID: 30862350
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.
    Isakova T; Xie H; Yang W; Xie D; Anderson AH; Scialla J; Wahl P; Gutiérrez OM; Steigerwalt S; He J; Schwartz S; Lo J; Ojo A; Sondheimer J; Hsu CY; Lash J; Leonard M; Kusek JW; Feldman HI; Wolf M;
    JAMA; 2011 Jun; 305(23):2432-9. PubMed ID: 21673295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fibroblast Growth Factor-23 and Carotid Artery Intima Media Thickness in Chronic Kidney Disease.
    Yilmaz G; Ustundag S; Temizoz O; Sut N; Demir M; Ermis V; Sevinc C; Ustundag A
    Clin Lab; 2015; 61(8):1061-70. PubMed ID: 26427152
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sun exposure influences the prognostic power of components of mineral metabolism in patients with coronary artery disease.
    Aceña A; Franco-Peláez JA; Gutierrez-Landaluce C; Pello AM; Cristóbal C; Tarín N; Huelmos A; Carda R; Martín-Mariscal ML; Alonso J; González-Parra E; González-Casaus ML; Lorenzo Ó; López Bescos L; Egido J; Tuñón J
    Nutr Metab Cardiovasc Dis; 2017 Sep; 27(9):762-767. PubMed ID: 28803689
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease.
    Tuñón J; Fernández-Fernández B; Carda R; Pello AM; Cristóbal C; Tarín N; Aceña Á; González-Casaus ML; Huelmos A; Alonso J; Lorenzo Ó; González-Parra E; Hernández-González I; Mahíllo-Fernández I; López-Bescós L; Egido J
    Diabetes Metab Res Rev; 2016 Oct; 32(7):685-693. PubMed ID: 26888181
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum fetuin-A and vitamin D in children with mild-to-severe chronic kidney disease: a cross-sectional study.
    Schaible J; Wigger M; Staude H; Drueckler E; Kundt G; Haffner D; Fischer DC
    Nephrol Dial Transplant; 2012 Mar; 27(3):1107-13. PubMed ID: 21750155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lower serum fibroblast growth factor-23 levels may suggest malnutrition in maintenance haemodialysis patients.
    Mizuiri S; Nishizawa Y; Yamashita K; Ono K; Oda M; Usui K; Shigemoto K
    Nephrology (Carlton); 2014 Sep; 19(9):568-73. PubMed ID: 24947687
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD.
    Isakova T; Gutierrez O; Shah A; Castaldo L; Holmes J; Lee H; Wolf M
    J Am Soc Nephrol; 2008 Mar; 19(3):615-23. PubMed ID: 18216315
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relation between fetuin-A levels and fibroblast growth factor 23 with the severity of coronary artery disease measured by SYNTAX scores.
    Chen YC; Lin FY; Lin RH; Chuang CL; Chang CC; Tsai CS
    Am J Cardiol; 2013 Oct; 112(7):950-3. PubMed ID: 23795812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study.
    Ix JH; Shlipak MG; Wassel CL; Whooley MA
    Nephrol Dial Transplant; 2010 Mar; 25(3):993-7. PubMed ID: 20037168
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study.
    Yasin A; Liu D; Chau L; Madrenas J; Filler G
    BMC Nephrol; 2013 Feb; 14():39. PubMed ID: 23413976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of renal function in primary hyperparathyroidism.
    Walker MD; Nickolas T; Kepley A; Lee JA; Zhang C; McMahon DJ; Silverberg SJ
    J Clin Endocrinol Metab; 2014 May; 99(5):1885-92. PubMed ID: 24527717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation.
    Young A; Hodsman AB; Boudville N; Geddes C; Gill J; Goltzman D; Jassal SV; Klarenbach S; Knoll G; Muirhead N; Prasad GV; Treleaven D; Garg AX;
    Am J Kidney Dis; 2012 Jun; 59(6):761-9. PubMed ID: 22093959
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fibroblast growth factor 23 is associated with the presence of coronary artery disease and the number of stenotic vessels.
    Hu X; Ma X; Pan X; Hao Y; Luo Y; Lu Z; Bao Y; Jia W
    Clin Exp Pharmacol Physiol; 2015 Nov; 42(11):1152-7. PubMed ID: 26217893
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiac Changes and Their Association with Fetuin-A and Fibroblast Growth Factor-23 in Children with Chronic Kidney Disease.
    Mudi A; Ntsinjana H; Dickens C; Levy C; Ballot D
    Nephron; 2017; 136(3):233-242. PubMed ID: 28402974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function.
    Dhayat NA; Ackermann D; Pruijm M; Ponte B; Ehret G; Guessous I; Leichtle AB; Paccaud F; Mohaupt M; Fiedler GM; Devuyst O; Pechère-Bertschi A; Burnier M; Martin PY; Bochud M; Vogt B; Fuster DG
    Kidney Int; 2016 Sep; 90(3):648-57. PubMed ID: 27370409
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fetuin-A as a risk factor for mortality in hemodialysis patients.
    Pecovnik Balon B; Knehtl M; Bevc S; Jakopin E; Gorenjak M
    Wien Klin Wochenschr; 2010 May; 122 Suppl 2():63-7. PubMed ID: 20517675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients.
    Tanaka H; Hamano T; Fujii N; Tomida K; Matsui I; Mikami S; Nagasawa Y; Ito T; Moriyama T; Horio M; Imai E; Isaka Y; Rakugi H
    Bone; 2009 Nov; 45(5):949-55. PubMed ID: 19631779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.